NasdaqGM:CRVSBiotechs
Corvus Pharmaceuticals (CRVS) Valuation Check After Positive Soquelitinib Data And Equity Raise
Corvus Pharmaceuticals (CRVS) is back in focus after early trial data for its oral eczema drug, soquelitinib, showed meaningful clinical benefit and a clean safety profile, followed by a sizeable equity raise to fund further development.
See our latest analysis for Corvus Pharmaceuticals.
The share price has surged over the past month, with a 30 day share price return of 235.56% and a 1 year total shareholder return of 375.38%. This suggests momentum has been building around the eczema data...